New Trial Revives Psychodynamic Therapy Debate

A new clinical trial has reignited a long-standing debate about the role of psychodynamic psychotherapy in treating schizophrenia. The study found that a modified version of the therapy showed promise for patients with schizophrenia-spectrum disorders.

For decades, psychodynamic therapy was considered ineffective for schizophrenia. During the 1960s and 1970s, it was a primary treatment. Later, rigorous studies failed to show benefits beyond standard care, with some research even linking it to increased suicidality. In a 1990 editorial, researchers Kim T. Mueser and Howard Berenbaum argued for a moratorium, comparing its efficacy profile to a drug that would be discarded.

The Evidence for a Shift

The landscape began to change with the rise of other therapies. A 2024 umbrella review confirmed cognitive behavioural therapy (CBT) as an evidence-based treatment for schizophrenia. The new 2026 German trial, however, presents fresh data. It was a prospective, single-centre, assessor-blinded, randomised controlled trial led by Dr. Montag and colleagues.

The study compared a modified psychodynamic psychotherapy against treatment as usual. The modified approach focused on present relationships and reality testing, moving away from classic techniques like deep interpretation of unconscious conflicts.

What the New Trial Found

The German research team reported that their adapted psychodynamic therapy led to significant improvements compared to standard care. The trial measured outcomes over a specific period, noting gains in patient functioning and symptom reduction. These findings directly challenge the historical consensus that psychodynamic methods have no place in schizophrenia treatment.

Earlier, smaller studies had hinted at potential benefits. A 1984 study by Gunderson and colleagues and a 2012 study by Rosenbaum and team both suggested some positive effects from supportive psychodynamic approaches, particularly for first-episode psychosis. The new trial provides stronger, more contemporary evidence.

The Ongoing Clinical Debate

Despite the new findings, the authors of the Lancet comment, Jan Ivar Røssberg and June Ullevoldsæter Lystad, urge caution. They note that one positive trial does not overturn a large body of negative historical evidence. The modified therapy used in the German study is distinct from traditional psychoanalysis, which remains unsupported.

The core question is whether this specific, modernized form of psychodynamic therapy can become a recommended, evidence-based option. The commentators state that more replication studies are needed before clinical guidelines can be updated. The debate now centres on defining which therapeutic components, if any, are effective.

The final word is not yet in. The research continues.